

Luna Labs: A high-throughput innovation engine for hard tech startups

100+ employees, 40% with advanced degrees

\$20M/year in non-dilutive contract funding

80+ patents, with product launches in multiple verticals

NanoVac

- Can be engineered to vaccinate against **multiple targets simultaneously**
- Controls antigen presentation and **enhances cellular uptake**
- Mimics virion size and shape to **stimulate antibody production**
- Stabilizes mRNA/proteins, enabling **cold-storage flexibility**
- Compatible with **intramuscular and intranasal** applications
- Easily produced with widely available and low-cost components and **designed to scale**

Asset

- NanoVac platform
- NV-V1V2; HIV-1 vaccine candidate


Indications

- HIV-1 V1V2 glycoprotein or mRNA
- Rapid transition to alternate antigens



Route

- Verified immune response and dosing for IM, IN, SC

Demonstrated biocompatibility, clearance, immunogenicity, and efficacy in preclinical models of HIV-1 vaccination



- NanoVac can deliver proteins, mRNA, or both simultaneously.
- Cellular transfection and *in vivo* immunogenicity is enhanced using this revolutionary delivery platform.
- Dosing studies of the vehicle indicate wide distribution, rapid clearance, and no signs of toxicity.
- In a HIS mouse model of HIV-1 vaccination, NV-V1V2 demonstrated protection against challenge.



NanoVac delivery of protein or mRNA can result in rapid and long-lasting immune response.

In a humanized mouse model of HIV-1 challenge, NanoVac delivery of mRNA encoding the V1V2 envelope glycoprotein resulted in protection against HIV-1 challenge.